Drugs /

dkn-01

Back to Drugs List

Overview

NCI Definition [1]:
A humanized monoclonal antibody directed against Wnt antagonist Dickkopf-1 (DKK1) with potential anti-osteolytic activity. DKK1-neutralizing monoclonal antibody DKN-01 binds to and inhibits DKK1, which restores Wnt pathway signaling. Reactivation of the Wnt signaling pathway may result in the differentiation and activation of osteoblasts within the bone matrix and the reversal of tumor-induced osteolytic disease. Elevated levels of circulating DKK1, a potent Wnt signaling pathway antagonist, is associated with a number of neoplastic diseases.

Clinical Trials

View Clinical Trials for dkn-01

Dkn-01 has been investigated in 7 clinical trials, of which 7 are open and 0 are closed. Of the trials investigating dkn-01, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open).

DKK1 Overexpression, DKK1 Expression, and APC Loss are the most frequent biomarker inclusion criteria for dkn-01 clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and esophageal adenocarcinoma are the most common diseases being investigated in dkn-01 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dkn-01
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dkn-01 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dkk1-neutralizing monoclonal antibody dkn-01
Drug Target(s) [2]:
DKK1
NCIT ID [1]:
C113331

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.